Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug
Executive Summary
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.
You may also be interested in...
Amarin Steps Closer To EU Cardiovascular Risk Market
The European Medicines Agency has recommended in favor of approval for Amarin’s fish-oil derivative, Vazkepa.
EU Approval Verdicts Near For A Bumper Crop Of New Drugs
Novartis, Arvelle, AstraZeneca and Incyte are among a raft of drug sponsors who should find out shortly whether the European Medicines Agency will vote in favor of approving their products for use in the EU.
Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.